Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited (NURPF) Company Profile & Overview
Explore Neuren Pharmaceuticals Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Neuren Pharmaceuticals Limited (NURPF) Company Profile & Overview
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.